TB-500 is a synthetic peptide based on thymosin beta-4, a naturally occurring protein involved in cell migration and repair. Like BPC-157, its reputation was built on animal research and athlete forums — not human trials — and it has no approved medical use.
Thymosin beta-4 has a real scientific literature: it regulates actin, a protein central to cell structure and movement, and animal studies report wound-healing and tissue-repair effects. TB-500, the synthetic research-market version, rides that literature — but controlled human evidence for the injury-recovery claims made in forums is lacking.
No approved human use, sold “for research only,” and firmly on the sports-doping radar: thymosin beta-4/TB-500 is prohibited under WADA rules and is best known publicly from doping cases in professional and equine sport.
Working out reconstitution or syringe units? Use the free peptide calculator, then check your batch’s published test result before trusting the label: in 2024, roughly 43% of research peptides submitted to Janoshik Analytical missed their label claims.
Vendor rankings on PeptideCensus are computed only from publicly published third-party lab results; see the vendor index and how scoring works.
TB-500 is half of the “wolverine stack” with BPC-157, covered in its own article: BPC-157 and TB-500.
In animal research: wound healing and tissue repair via thymosin beta-4 biology. Human evidence for the recovery claims is lacking.
TB-500 is a synthetic product based on thymosin beta-4 (commonly its active fragment); vendors use the names loosely, which is itself a reason to demand batch testing.
Yes: prohibited under WADA rules and a known doping-test risk.
Different molecules with different proposed mechanisms, usually discussed together because forums stack them. See the stack article for the comparison.
PeptideCensus aggregates publicly published third-party lab results and links every number to its source. Nothing on this page is medical advice; research compounds are not for human use.